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Objectives: The primary aim of this prospective multi-centre study involving patients undergoing elective abdominal 
aortic aneurysm (AAA) surgery was to investigate the relationship between intraoperative intravenous heparinisation, 
blood loss during surgery and thrombotic omplications. 
Methods: Two hundred and eighty-four patients were randomised to receive intravenous heparin (n = 145) or no heparin 
(n = 139). Groups were evenly matched for age, sex, weight, aneurysm size, haemoglobin concentration, platelet counts and 
distal occlusive disease measured by ankle/brachial systolic pressure. 
Results: There were no statistically significant differences in blood loss (median 1400 ml vs. 1500 ml; z = 0.02, p = 0.98, 
95% C.L = -200 to 200), blood transfused (4.0 units vs. 4.0 units; z = 1.09, p = 0.28, 95% C.I. = -1 to O) or distal 
thrombosis between the two groups. However, analysis of the clinical outcome revealed that 5.7% of the non-heparin group 
but only 1.4% of the heparinised patients uffered afatal perioperative myocardial infarction (MI); p < 0.05. All MI, 
including non fatal events, affected 8.5% and 2% respectively (p = 0.02). 
Conclusions: Heparin does not increase blood loss or the need for blood transfusion during surgery. Heparin is not 
necessary to prevent distal thrombosis when the aorta is cross clamped. The results of the study are consistent with the 
known mechanisms leading to intraoperative MI and strategies for its prevention. Intravenous heparin, given before aortic 
cross clamping, is an important prophylaxic against perioperative MI in relation to AAA surgery. 
Introduction 
Intravenous heparin is administered during vascular 
reconstruction to prevent thrombosis due to stasis 
distal to occluding clamps. Some clinicians, however, 
are concerned that heparin may increase bleeding and 
so lead to postoperative complications and more 
blood transfusions. Homologous blood transfusion 
should be avoided if possible in modern surgical 
practice because of the infective risks of blood and the 
immune suppression related to its use. 1"2 Recently it 
has been shown that blood transfusion i creases the 
incidence of perioperative infective complications. B 
These are an important source of morbidity following 
major vascular surgery; infection of a vascular pros- 
thesis is potentially lethal. The practice of using no 
heparin at all during aortic operations is becoming 
more popular amongst many surgeons, especially in 
Europe, and is routine in thoracoabdominal aortic 
aneurysm repair. Some surgeons adopt an inter- 
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mediate stance by injecting heparin distal to the 
occluding clamps in an attempt to create local hepar- 
inisation without systemic effects. The variation in 
practice in the U.K. was documented in a recent postal 
survey. 4 Of 215 responders to the survey ques- 
tionnaire, 19 never used heparin and 45 used distal 
heparinization. Of the 151 who used systemic heparin, 
68 used 5000 units and the remainder gave doses 
varying between 400 and 20000 units. Twenty nine 
responders administered a dose based on the patient's 
body weight. 
There is little reliable information concerning bleed- 
ing or thrombosis and their relationship to intra- 
operative heparin in the scientific literature. One 
report of a retrospective survey suggested that there 
was no excess risk of bleeding even with high doses of 
heparin, 5 but there are no data regarding the risk of 
distal thrombosis when heparin is not used. 
The aim of this study was to investigate he effect of 
intravenous heparin on perioperative bleeding and 
thrombus by means of a prospective randomised 
multi-centre trial. Elective infrarenal AAA grafting 
was selected as this operation commonly involves 
blood loss of between 1000 and 2000 ml and both non- 
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surgical bleeding and distal thrombosis are important 
causes of postoperative morbidity and mortality. The 
study was performed in 12 centres, each with a 
vascular service staffed by experienced surgeons who 
were members of the Joint Vascular Research Group 
(JVRG). The JVRG is a group of vascular surgeons 
committed to collaborative research into problems of 
direct clinical relevance to current practice. 
Patients and Methods 
After agreement on the protocol, contributing sur- 
geons obtained local ethical committee agreement and 
all patients gave informed consent. Two hundred and 
eighty-four patients undergoing primary surgery for 
elective repair of AAA were randomised by sealed 
envelope to receive either the surgeon's normal 
intraoperative heparin regimen or no heparin at all. 
Those taking aspirin, non-steroidal nti-inflammatory 
drugs, or who had a history of a bleeding tendency 
were excluded. 
Age, sex and weight were recorded. The maximum 
diameter of the aneurysm was measured using either 
ultrasound or CT-scanning. The status of the runoff 
vessels to the lower limb was measured using Doppler 
derived ankle brachial pressure indices (ABPI) in 164 
cases and by careful pulse palpation in the 
remainder. 
Haemoglobin, haematocrit and platelet counts were 
measured before operation, 24 h and 1 week after 
operation. Blood loss was estimated by weighing 
swabs and measuring suction loss, and the volume of 
bank blood actually transfused was recorded. The 
duration of the operation, graft material used, opera- 
tion performed and technical difficulties encountered 
during the operation were noted. 
After the operation, ABPI, the presence of distal 
atheroembolism (trash foot), pulmonary embolism 
confirmed by ventilation/perfusion scanning, and 
renal, respiratory and cardiac events were specifically 
noted on the proforma over a follow up period of 30 
days. 
Completed forms were collated and checked by a 
trials co-ordinator who was not involved in the clinical 
management of any of the patients. The information 
was coded and transferred to a computer for verifica- 
tion and subsequent analysis, using the statistical 
package SPSS/PC + (version 4.0). 6 Data  were  ana- 
lysed using the Mann-Whitney U-test or the Chi- 
squared test. 
Table 1. Factors which may have influenced blood loss were 
evenly distributed between the two groups. Most grafts were 
woven low porosity Dacron. The overall frequency of 
inflammatory aneurysms was 6% 
Heparin (n=145) Non-heparin (n=139) 
Aneurysm size (cm) 6.42+1.78 (n=143) 6.49_+1.94 (n=135) 
Male:Female 119:26 122:17 
Tube Graft 86 77 
Bi-iliac 30 32 
Bifemoral 11 8 
Sealed graft 17 10 
Knitted graft 2 3 
Inflammatory 6 9 
Results 
Two hundred and eighty-four patients completed the 
study of which 145 received 5000 iu heparin before 
aortic cross-clamping. Following consent and rando- 
misation there were no withdrawals, but two patients 
initially randomised to no heparin were heparinised 
during lengthy and complex reconstructions. Thirteen 
heparin patients had their heparin reversed at the end 
of the reconstruction with a half dose (25 mg) 
protamine sulphate. Data were analysed on an inten- 
tion to treat basis. 
Variables which may have affected blood loss were 
evenly balanced (Table 1). Aneurysms tended to be 
large (>6 cm diameter) and the majority were 
replaced with a woven Dacron tube graft. 
Blood loss was a median of 1400 ml (n=140, 
interquartile range 1000-2000 ml) in the heparin group 
and 1500 ml (893-2000 ml) in the non-heparin group 
(z = 0.02, p = 0.98, 95% C.I. = -200 to 200). Four units of 
blood (3.0-6.0) were transfused in heparinised 
patients (n = 94) and 4.0 units (4.0-6.0) were also given 
to non-heparinised patients (n =-93, z = 1.09, p = 0.28, 
95% C.I. =-1 to 0). There was no difference between 
the two groups with regard to haemoglobin, haema- 
tocrit and platelet counts preoperatively, postoper- 
atively, at 24 h and 1 week after operation. From 
median preoperative haemoglobin levels of 13.9 g/dl  
(heparin n = 139) and 14.0 g/dl  (no heparin n = 138), 
patients were discharged with haemoglobin levels of 
12.4 g/dl  (n = 130) and 12.4 g/dl  (n = 129) respectively. 
This reflects a comparable transfusion policy between 
the two treatment groups. 
During the operation, clinically significant bleeding 
(defined subjectively by the operator) was encoun- 
tered in eight heparin and 13 non-heparin patients. 
One heparinised and three non-heparinised patients 
required an additional distal graft. Eight non-heparin 
and three heparinised patients required embolectomy 
to remove distal thrombus, and there were three (non- 
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Table 2. Postoperative Doppler derived peak systolic blood 
pressures (mmHg) were similar in the two groups. (PT=Posterior 
Tibial artery; DP=Dorsalis Pedis artery). Preoperative data were 
similar. Values in parentheses are ranges 
Median (IQR) 
Heparin A Non Heparin B 
Brachial 140 (130-160) 106 140 (130-160) 103 
Right PT 148 (129-160) 74 145 (120-160) 73 
Right DP 150 (128-160) 77 150 (126-170) 62 
Left PT 150 (130-170) 80 160 (139-170) 68 
Left DP 150 (130-160) 75 150 (130-170) 63 
heparin) and four (heparin) cases of atheroembolism, 
all of which responded to conservative management 
without the need for amputation. None of these 
differences were statistically significant. 
Operations in the heparinized patients took slightly 
longer than non-heparin cases (120 min (90-150 min, 
n = 129) vs .  105 rain (90-125 min, n--128)) but this 
trend just escaped statistical significance (z= 1.89, 
p = 0.06, 95% C.I. = 0 to 15). Hospital stay was a median 
of 10 days in both groups. 
Despite the concern that the lack of heparin's 
protection might lead to distal arterial thrombosis, 
there was no clinical evidence to support his, and the 
preservation of the lower limb circulation was 
reflected by similar ankle-branchial pressure values in 
the two groups (Table 2). 
The 30 day morbidity and mortality were recorded 
for each group and are shown in Table 3. There were 
more non fatal myocardial infarctions (MI) in the non- 
heparin group, but this difference was not significant. 
However, there were eight fatal MI in this group 
compared to two in heparinised patients (5.7% vs .  
1.4%; differences in proportions 4.3%, 95% confidence 
interval 0.06-8.6%, p= 0.06; Fisher exact est). If all MI 
are compared, the difference was more marked -8.5% 
vs .  2.0%; differences in proportions 6.5%, 95% C.I. 
1.3-12% (p = 0.02). 
The diagnosis was checked by reference to the 
original case record and/or post mortem examination. 
Non-fatal MI were diagnosed clinically; there was no 
routine ECG or enzyme analysis in all of the patients 
so a number of silent infarcts may have been missed. 
Further analysis of the records of the deceased 
patients howed that, in the heparinised patients, MI 
occurred in the context of multiple system failure in 
the intensive care unit, whereas in the non-heparin 
group. MI occurred as a primary event, usually during 
operation. 
As this surprising result was serendipitous and 
outside the original study design, no stratification for 
cardiac risk factors was available for analysis, but in 
Table 3. Analysis of clinical data revealed an excess of 
myocardial infarctions in non-heparinised pateints. One non- 
heparin patient died after uncontrolled bleeding and a 
heparinised patient succumbed to a thoracic aortic dissection 
postoperatively 
Heparin (n=145) Non-heparin (n=139) 
Morbidity 
Myocardial infarct 1 4 
Other cardiac 3 2 
Pulmonary embolus 0 2 
Respiratory 2 3 
Renal failure 4 2 
Graft infection (early) 1 1 
Miscellaneous 4 5 
Mortality 
Myocardial infarct 2 8* 
Acute renal failure 2 1 
Respiratory failure 1 1 
Other 1 1 
Overall mortality 4.2% 7.8 % 
*p=0.05 (Mann-Whitney). 
view of the large numbers in the two categories it is 
felt that the groups should be comparable. 
Discussion 
The study provides useful information regarding the 
management of AAA in the U.K. In this non-selected 
group of consecutive patients, operated AAA tended 
to be large (6.4 cm) and were repaired using a woven 
tube graft. The incidence of inflammatory aneurysms 
(6%) is in agreement with other series. 
The overall complication and mortality rate in the 
heparin group compares well with the contemporary 
literature 7-9 and supports the recommendations of the 
CEPOD 1° report that elective aortic surgery should be 
performed by experienced surgeons and 
anaesthetists. 
Although, a priori, heparin would be expected to 
increase bleeding, many surgeons are prepared to 
operate on anticoagulated patients. Vascular surgeons 
often extend their dissection after heparin has been 
given; excessive bleeding is not usually encountered. 
The lack of objective data in the literature prompted 
this study, especially in the current atmosphere of 
blood conservation and concerns over the safety of 
homologous blood. 
There was no difference between the two groups in 
terms of blood transfused, blood lost, and bleeding 
complications, and the only death related to bleeding 
occurred in the non-heparin group. If heparin does 
increase any aspect of surgical bleeding, it may lead to 
oozing or bruising. Antiplatelet drugs, especially 
aspirin, are much more likely culprits, and most 
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surgeons would counsel against aortic surgery in 
aspirinated patients; none of the patients reported in 
this study were known to be taking aspirin at the time 
of their operations. Oozing and bruising are difficult 
to measure objectively, but it is tempting to speculate 
that the increased operation time noted in the hep- 
arinised patients was due to time spent with the 
diatherm?4 especially on closure of the wounds. Half 
the contributing surgeons used low dose subcuta- 
neous heparin as a routine for postoperative thrombo- 
prophylaxis. Unfortunately this was not recorded on 
the proforma and should be noted in future studies. 
The safety of intraoperative heparin in this large 
study supports those who advocate its use to facilitate 
intraoperative autotransfusion, especially using sim- 
ple canister devices such as Solcotrans; adequate 
heparinisation is vital to prevent clotting in these 
systems. 
The original concerns over the possibility of 
increased bleeding with heparin, and perhaps more 
importantly, worries about the toxicity and direct 
anticoagulant effects of protamine sulphate, 11 has led 
many surgeons to avoid heparin altogether. The study 
was, therefore, also designed to identify thrombotic 
complications which would be expected to arise in the 
non-heparin group. Ankle brachial pressures, which 
are a sensitive indicator of lower limb thrombosis, 
were measured; there was no difference between the 
groups. It is important to keep arterial clamps in place 
to maintain static blood in contact with the intima of 
the distal vessel which inhibits coagulation, and not 
to expose it to clot in the pelvis, which strongly 
promotes coagulation. 
Research often yields unexpected results whose 
validity may be impossible to judge given the original 
study design. The discovery of a large number (eight) 
primary MI in the non-heparin group was surprising 
and serendipitous. The large numbers in each group 
made the differences tatistically significant and it is 
relevant hat the infarcts in the heparinised group all 
occurred in the clinical context of multiple system 
dysfunction in the postoperative period. The overall 
mortality in this group (4.2%) compares well with 
published series. The postoperative deaths were well 
documented as the patients were in an intensive care 
unit or operating theatre. Routine post operative 12 
lead electrocardiograms and cardiac enzymes were 
not measured in all cases, so the incidence of unrecog- 
nised non-fatal MI is unknown in either group. 
However, as each centre randomised adequate num- 
bers (except wo who only entered one patient each) it 
is probable that there was no bias. The same criticism 
may be levelled with regard to cardiac risk stratifica- 
tion, which was not done, but again the numbers are 
large and bias is unlikely. 
The role of low-dose subcutaneous heparin, given 
as prophylaxis against thromboembolism, is unclear 
in patients undergoing aortic aneurysm repair. The 
practice of individual surgeons was not originally 
recorded. Contributors were therefore re-contacted; 
six of the 11 used no heparin prophylaxis at the time of 
the stud~ and again, as each centre randomised a
median of 26 patients, this probably has no bearing on 
the outcome, both in terms of MI and of blood loss. 
The mechanism by which intravenous heparin 
prevents MI during aortic surgery remains spec- 
ulative, but it is possible that it prevents propagation 
of thrombus in the coronary arteries. This may occur 
when dilatation of the left ventricle, which follows 
aortic cross-clamping, leads to distortion of athero- 
sclerotic coronary arteries and plaque fissuring. The 
fissure in the atherosclerotic plaque exposes procoagu- 
lants in the diseased media. If this is so, heparin could 
be useful in suprarenal aneurysm repair and in other 
operations involving aortic clamping where it is not 
currently used. The theory also strongly supports 
strategies designed to monitor and regulate left 
ventricular work, and therefore ventricular dilatation, 
during aortic surgery, such as suprasternal or trans- 
oesophageal Doppler. 
In conclusion, this study suggests that the use of 
intraoperative heparin during elective aortic aneu- 
rysm repair may act as a prophylaxis against myocar- 
dial infarction. The primary aim of the study was to 
quantify the bleeding which could be attributed to 
heparin. The use of heparin will not increase the risk 
of blood loss. Conversely, if heparin is not used there 
is no increased risk of distal thrombosis or venous 
thromboembolism. Further studies into strategies to 
reduce the incidence of perioperative MI using anti- 
coagulation are required. 
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